{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T03:24:11Z","timestamp":1648524251827},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2013,7,10]],"date-time":"2013-07-10T00:00:00Z","timestamp":1373414400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s00108-013-3327-3","type":"journal-article","created":{"date-parts":[[2013,7,8]],"date-time":"2013-07-08T12:03:48Z","timestamp":1373285028000},"page":"1011-1015","source":"Crossref","is-referenced-by-count":0,"title":["Husten, Atemnot und B-Symptome bei einer 40-j\u00e4hrigen Frau"],"prefix":"10.1007","volume":"54","author":[{"given":"A.","family":"Wolfensberger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Benz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.W.","family":"Russi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Tinguely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Keller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,7,10]]},"reference":[{"key":"3327_CR1","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1182\/blood-2010-07-290213","volume":"116","author":"Bower","year":"2010","unstructured":"Bower M (2010) How I treat HIV-associated multicentric Castleman disease. Blood 116:4415\u20134421","journal-title":"Blood"},{"key":"3327_CR2","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/1097-0142(195607\/08)9:4<822::AID-CNCR2820090430>3.0.CO;2-4","volume":"9","author":"Castleman","year":"1956","unstructured":"Castleman B, Iverson L, Menendez VP (1956) Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 9:822\u2013830","journal-title":"Cancer"},{"key":"3327_CR3","first-page":"293","volume":"142","author":"Dispenzieri","year":"2008","unstructured":"Dispenzieri A (2008) Castleman disease. Cancer Treat Res 142:293\u2013330","journal-title":"Cancer Treat Res"},{"key":"3327_CR4","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/ajh.23291","volume":"87","author":"Dispenzieri","year":"2012","unstructured":"Dispenzieri A, Armitage JO, Loe MJ et\u00a0al (2012) The clinical spectrum of Castleman\u2019s disease. Am J Hematol 87:997\u20131002","journal-title":"Am J Hematol"},{"key":"3327_CR5","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/cid\/cis1009","volume":"56","author":"Dossier","year":"2013","unstructured":"Dossier A, Meignin V, Fieschi C et\u00a0al (2013) Human herpesvirus 8-related Castleman disease in the absence of HIV infection. Clin Infect Dis 56:833\u2013842","journal-title":"Clin Infect Dis"},{"key":"3327_CR6","doi-asserted-by":"crossref","unstructured":"Gerard L, Berezne A, Galicier L et\u00a0al (2007) Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman\u2019s disease: ANRS\u00a0117 CastlemaB Trial. J\u00a0Clin Oncol 25:3350\u20133356","DOI":"10.1200\/JCO.2007.10.6732"},{"key":"3327_CR7","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1182\/blood-2011-02-333633","volume":"118","author":"Hoffmann","year":"2011","unstructured":"Hoffmann C, Schmid H, Muller M et\u00a0al (2011) Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease. Blood 118:3499\u20133503","journal-title":"Blood"},{"key":"3327_CR8","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1182\/blood.V78.11.2923.2923","volume":"78","author":"Leger-Ravet","year":"1991","unstructured":"Leger-Ravet MB, Peuchmaur M, Devergne O et\u00a0al (1991) Interleukin-6 gene expression in Castleman\u2019s disease. Blood 78:2923\u20132930","journal-title":"Blood"},{"key":"3327_CR9","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood-2004-12-4602","volume":"106","author":"Nishimoto","year":"2005","unstructured":"Nishimoto N, Kanakura Y, Aozasa K et\u00a0al (2005) Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106:2627\u20132632","journal-title":"Blood"},{"key":"3327_CR10","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","volume":"112","author":"Nishimoto","year":"2008","unstructured":"Nishimoto N, Terao K, Mima T et\u00a0al (2008) Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112:3959\u20133964","journal-title":"Blood"},{"key":"3327_CR11","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nrclinonc.2010.103","volume":"7","author":"Schulte","year":"2010","unstructured":"Schulte KM, Talat N (2010) Castleman\u2019s disease \u2013 a two compartment model of HHV8 infection. Nat Rev Clin Oncol 7:533\u2013543","journal-title":"Nat Rev Clin Oncol"},{"key":"3327_CR12","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1182\/blood.V86.4.1276.bloodjournal8641276","volume":"86","author":"Soulier","year":"1995","unstructured":"Soulier J, Grollet L, Oksenhendler E et\u00a0al (1995) Kaposi\u2019s sarcoma-associated herpesvirus-like DNA-sequences in multicentric Castlemans disease. Blood 86:1276\u20131280","journal-title":"Blood"},{"key":"3327_CR13","doi-asserted-by":"crossref","unstructured":"Van Rhee F, Fayad L, Voorhees P et\u00a0al (2010) Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman\u2019s disease. J\u00a0Clin Oncol 28:3701\u20133708","DOI":"10.1200\/JCO.2009.27.2377"},{"key":"3327_CR14","first-page":"486","volume":"8","author":"Van","year":"2010","unstructured":"Van Rhee F, Stone K, Szmania S et\u00a0al (2010) Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy. Clin Adv Hematol Oncol 8:486\u2013498","journal-title":"Clin Adv Hematol Oncol"},{"key":"3327_CR15","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1182\/blood.V74.4.1360.1360","volume":"74","author":"Yoshizaki","year":"1989","unstructured":"Yoshizaki K, Matsuda T, Nishimoto N et\u00a0al (1989) Pathogenic significance of interleukin-6 (IL-6\/BSF-2) in Castleman\u2019s disease. Blood 74:1360\u20131367","journal-title":"Blood"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-013-3327-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-013-3327-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-013-3327-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T01:25:38Z","timestamp":1596072338000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-013-3327-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,10]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["3327"],"URL":"https:\/\/doi.org\/10.1007\/s00108-013-3327-3","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,10]]}}}